Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I.

Lancet. 2010 May 29;375(9729):1896-905. doi: 10.1016/S0140-6736(10)60357-1.

PMID:
20511019
2.

Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.

Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I.

J Infect Dis. 2006 Jun 15;193(12):1650-7. Epub 2006 May 10.

PMID:
16703508
3.

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.

4.

Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.

Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S.

PLoS Pathog. 2006 Jan;2(1):e1. Epub 2006 Jan 13.

5.

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H.

J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.

6.

Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.

Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-DiCaprio KM, Cassell GH, Jahrling PB, Geisbert TW.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S390-9.

PMID:
17940975
7.

A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection.

Warren TK, Whitehouse CA, Wells J, Welch L, Heald AE, Charleston JS, Sazani P, Reid SP, Iversen PL, Bavari S.

MBio. 2015 Feb 10;6(1). pii: e02344-14. doi: 10.1128/mBio.02344-14.

8.

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, Saijo M, Feldmann F, Brining D, Feldmann H, Takada A.

PLoS One. 2012;7(4):e36192. doi: 10.1371/journal.pone.0036192. Epub 2012 Apr 27.

9.

Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.

Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM.

J Virol. 2008 Jun;82(11):5664-8. doi: 10.1128/JVI.00456-08. Epub 2008 Apr 2.

11.

Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.

Tsuda Y, Safronetz D, Brown K, LaCasse R, Marzi A, Ebihara H, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1090-7. doi: 10.1093/infdis/jir379.

12.

Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.

Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374. Epub 2016 Aug 28.

13.

Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.

Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.

14.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Thi EP, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Fenton KA, Kondratowicz AS, MacLachlan I, Geisbert TW, Mire CE.

Nat Microbiol. 2016 Aug 22;1(10):16142. doi: 10.1038/nmicrobiol.2016.142.

15.

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S.

Antimicrob Agents Chemother. 2009 May;53(5):2089-99. doi: 10.1128/AAC.00936-08. Epub 2009 Feb 17.

16.

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW.

Nature. 2015 May 21;521(7552):362-5. doi: 10.1038/nature14442. Epub 2015 Apr 22.

17.

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1066-74. doi: 10.1093/infdis/jir348.

18.

Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification.

Kurosaki Y, Takada A, Ebihara H, Grolla A, Kamo N, Feldmann H, Kawaoka Y, Yasuda J.

J Virol Methods. 2007 Apr;141(1):78-83. Epub 2006 Dec 27.

PMID:
17194485
19.

A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.

Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1275. doi: 10.1371/journal.pntd.0001275. Epub 2011 Aug 9.

20.

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW.

Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

Supplemental Content

Support Center